Omnicell (OMCL) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Omnicell (OMCL) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | 21.54% |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | 48.31% |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | 64.80% |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | 13.50% |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | 14.62% |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | 124.64% |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | 0.99% |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | -11.16% |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | -15.62% |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | 59.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.78% |
| Mar 31, 2026 | 110.23% |
| Dec 31, 2025 | -46.10% |
| Sep 30, 2025 | 24.23% |
| Jun 30, 2025 | -27.16% |
| Mar 31, 2025 | -48.10% |
| Dec 31, 2024 | 46.60% |
| Sep 30, 2024 | -60.09% |
| Jun 30, 2024 | -19.48% |
| Mar 31, 2024 | 291.17% |
| Dec 31, 2023 | -53.24% |
| Sep 30, 2023 | 169.22% |
| Jun 30, 2023 | 863.30% |
| Mar 31, 2023 | 179.83% |
| Dec 31, 2022 | 37.77% |
| Sep 30, 2022 | -50.74% |
| Jun 30, 2022 | -113.31% |
| Mar 31, 2022 | -127.86% |
| Dec 31, 2021 | -22.00% |
| Sep 30, 2021 | 17.18% |